Over the past decades financial investment of non-financial businesses has been rising and accumulation of capital goods has been declining. The first part of the paper offers a novel theory to explain this phenomenon. Financialization, the shareholder revolution and the development of a market for corporate control have shifted power to shareholders and thus changed management priorities, leading to a reduction in the desired growth rate. In the second part the link between accumulation and financialization is tested econometrically by means of a time series analysis of aggregate business investment for USA, UK, France, and Germany. Extensive test of robustness are performed. For the first three countries evidence that confirms the negative effect of financialization on accumulation is found. (author's abstract) / Series: Working Papers Series "Growth and Employment in Europe: Sustainability and Competitiveness"

The paper investigates the relation between effective demand, income distribution and unemployment empirically. Its aim is to evaluate Keynesian, Kaldorian and neoclassical hypotheses about the determination of labor market variables. To do so, a vector autoregression model consisting of capital accumulation, capacity utilization, the profit share, unemployment and the growth of labor productivity is estimated. A general post-Keynesian model following the lines of Kalecki and Kaldor is presented and provides the specification for a structural VAR. The model is estimated for the USA, UK and France. (authors' abstract) / Series: Working Papers Series "Growth and Employment in Europe: Sustainability and Competitiveness"

Die Mastzellen der Haut sind bedeutende Immuneffektorzellen in der Pathogenese der Caninen Atopischen Dermatitis (CAD; OLIVRY et al. 1997). Diese Zellen schütten in der Sofort- und in der Spätphase der Überempfindlichkeitsreaktion des Typs I Entzündungsmediatoren aus. Diätetisch verabreichte Fettsäuren werden in zelluläre Membranen eingebaut und sind somit in der Lage, die Produktion und Freisetzung dieser Entzündungsmediatoren zu beeinflussen. In der Praxis konnte gezeigt werden, dass eine diätetische Ergänzung von n6- und n3-Fettsäuren im Verhältnis von 5 zu 1 eine Linderung der klinischen Symptomatik bei 40% der an CAD leidenden Hunde herbeiführte (SCOTT et al. 1997). Das Ziel der vorliegenden Arbeit war es, zu überprüfen, welche Auswirkungen der Einbau supplementierter n6- und n3-Fettsäuren auf die Fettsäurenzusammensetzung und die Prostaglandinfreisetzung caniner Mastocytomzellen (C2) hat und ob diese Zellen in Bezug auf ihren Fettsäurenstoffwechsel als Modell für die CAD geeignet sind. Die Kultivierung der Zellen erfolgte in einem Grundmedium (DEH) oder in mit 14 µM Linol- (C18:2n6, DEH-LA), Gammalinolen- (C18:3n6, DEH-GLA), Arachidon- (C20:4n6, DEH-AA), a-Linolen- (C18:3n3, DEH-LnA), Eicosapentaen- (C20:5n3, DEH-EPA) oder Docosahexaensäure (C22:6n3, DEH-DHA) angereichertem Medium. Das Wachstum der C2 wurde in allen Kulturmedien über 11 Tage kontrolliert. Für die weiteren Untersuchungen wurden die Zellen am 4. bzw. 8. Tag geerntet, zweimal mit phosphatgepufferter Kochsalzlösung gewaschen und anschließend unter Stickstoff getrocknet. Die Ermittlung der Fettsäurenzusammensetzung der C2 erfolgte mittels Gaschromatographie nach Extraktion und Umesterung der Phospholipide. Dabei wurde L-a-Phosphatidylcholin-C17:0 als Interner Standard genutzt. Für die Bestimmung der Prostaglandine (PG) D2 und E2 wurden die Zellen mit dem Wespengift Mastoparan stimuliert. PGD2 wurde mittels eines PGD2-Methoxim-Enzym-Immunoassay (EIA) und PGE2 wurde mit Hilfe eines Radio-Immunassays (RIA) bestimmt. Die C2 zeigten in allen Kulturmedien eine Vermehrung lebender Zellen bis zum 8. Kultivierungstag, danach nahm die Zahl der abgestorbenen Zellen deutlich zu. Die Fettsäurensupplementierung beeinflusste das Zellwachstum nicht. Die erhöhte Zufuhr der Fettsäuren bewirkte eine Konzentrationserhöhung der entsprechenden Fettsäuren in den C2 (LA 4,9-fach, GLA 6,9-fach, AA 6-fach, LnA 9,3-fach, EPA 6,5-fach, DHA 8,4-fach). Weiterhin wurden signifikante Erhöhungen von Fettsäurenmetaboliten, die über die Elongasen und die D6-Desaturase aus den zugegebenen Fettsäuren gebildet werden, in den C2 gefunden. Produkte der D5-Desaturase waren dagegen nur in geringen Mengen nachweisbar. Ein zeitabhängiger Effekt des Einbaus der geprüften supplementierten Fettsäuren konnte nur für LA festgestellt werden, welche nach 8 Tagen in DEH-LA kultivierten C2 signifikant stärker eingebaut wurde als nach 4 Tagen. Die vorliegenden Ergebnisse lassen die Schlussfolgerung zu, dass in den C2 eine geringe Aktivität der D5-Desaturase vorliegt. Da eine niedrige Aktivität dieser Desaturase als möglicher Pathogenesemechanismus für das Auftreten der CAD verantwortlich gemacht wird, erscheinen die C2 als Modell für weitere Untersuchungen der CAD geeignet. Die durch Mastoparan stimulierte Freisetzung von PGE2 der C2 war bei der Kultivierung der Zellen im DEH-LnA und DEH-DHA signifikant erniedrigt und im DEH-AA und DEH-EPA signifikant erhöht. Die Ursache für die unterschiedlichen PGE2-Konzentrationen in C2 nach dem Zusatz der verschiedenen n3-Fettsäuren (LnA, EPA, DHA) ist bisher unklar. Verschiedene Möglichkeiten der Beeinflussung des Prostaglandinstoffwechsels durch diese Fettsäuren werden diskutiert. Auf Grund der erhaltenen Ergebnisse können die C2 als Modell genutzt werden, um die Mechanismen der Produktion von Prostaglandinen oder anderen Entzündungsmediatoren näher zu untersuchen und somit zur Erforschung der Pathogenesemechanismen der atopischen Dermatitis des Hundes sowie des Menschen beizutragen. / Cutaneous mast cells are considered as key immune effector cells in the pathogenesis of canine atopic dermatitis (CAD; OLIVRY et al. 1997). These cells release immediate-phase and late-phase mediators of inflammation. Dietary fatty acids are incorporated in cellular membranes and seem to influence mediator production and release. A dietary intervention with n6- and n3-fatty acids with a ratio from 5 to 1 alleviated clinical symptoms in 40% of atopic dogs (SCOTT et al. 1997). The purpose of this study was to examine the effects of n6- and n3-fatty acids on the fatty acid composition and the production of prostaglandins in canine mastocytoma cells (C2) as a possible model for CAD. Cells were cultured in a basic medium (DEH) or with additional 14 µM linoleic (C18:2n6, DEH-LA), gammalinolenic (C18:3n6, DEH-GLA), arachidonic (C20:4n6, DEH-AA), a-linolenic (C18:3n3, DEH-LnA), eicosapentaenoic (C20:5n3) or docosahexaenoic acid (C22:6n3, DEH-DHA). Cell growth was examined for 11 days in all media. The cells were harvested after 4 or 8 days, washed twice with phosphated buffered saline and dried under nitrogen for fatty acid analysis. The fatty acid composition was determined by gas chromatography after extraction and transesterification of the phospholipids using di-C17-phosphatidylcholin as internal standard. For measurment of prostaglandin (PG) D2 and E2 the C2 were stimulated with the wasp venom peptide mastoparan. PGD2 was measured by PGD2-methoxim-enzymimmunoassay (EIA) and PGE2 was determined by radioimmunoassay (RIA). Cell growth increased from day 1 to 8 and decreased thereafter in all media conditions. The supplied fatty acid did not influence the cell growth. Added fatty acids increased the concentration of these fatty acids in C2 (LA 4.9-fold, GLA 6.9-fold, AA 6-fold, LnA 9.3-fold, EPA 6.5-fold, DHA 8.4-fold). Futhermore elongated and D6-desaturated products of the corresponding fatty acids were significantly elevated, however D5-desaturated products were not measurable. An increased time dependent incorporation was only detectable for LA after culturing C2 in DEH-LA. The results let us assume that C2 has no activity of the D5-desaturase. If the assumed low activity of these desaturase is one of the mechanisms underlying the pathogenesis of CAD, C2 seems to be an adequate model for CAD. The production of PGE2 after stimulation with mastoparan was significantly reduced when C2 were cultured in DEH-LnA and DEH-DHA and was significantly increased when C2 were cultured in DEH-AA and DEH-EPA. The reason for the different PGE2-production in C2 after the treatment with the n3-fatty acids (LnA, EPA or DHA) being unsettled. The observed results suggest, that C2 could be used to investigate the mechanisms of production and release of prostaglandins or other mediators as a model to improve our understanding of the pathogenesis of canine or human atopic dermatitis.

Colorectal cancer, among other tumors, is characterized by elevated levels of prostaglandins due to the up-regulation of cyclooxygenase -2 (COX-2), a key enzyme in the eicosanoid biosynthesis pathway. Prostaglandin E2 (PGE2) is an important prostaglandin that exerts its biological function via four transmembrane G protein coupled receptors (EP1-4), among which the EP4 receptor is the most important. The relevance of EP4 receptor to the carcinogenic process and the consequences of its interaction with PGE2 were explored in this dissertation.Despite the importance of the EP4 receptor in colon carcinogenesis, studies looking at the receptor expression during cancer progression have not been extensive. One study showed that the protein levels of EP4 receptor were elevated in colon cancer whereas another study indicated that mRNA levels were decreased in tumor compared to normal. We expanded these observations and now report that the elevated protein levels of EP4 receptor in cancer are due to increased translation of proteins.In addition, we identified S100P as a novel downstream target of the PGE2/EP4 receptor signaling pathway. S100P has been previously implicated in a number of gastro-intestinal cancers such as pancreatic, gastric and colon cancers. However, its regulation via the PGE2/EP4 receptor signaling pathway has never been investigated. Here, we show that PGE2 via the EP4 receptor signaling leads to the transcriptional activation of S100P and that this activation happens exclusively in the presence of CREB. In summary, this dissertation brings to light novel therapeutic targets which could be used as potential markers to stratify colon cancer patients as well as avenues for clinical intervention for the management of colon carcinogenesis.

No description available.

L’arthrose (OA) est une maladie dégénérative et multifactorielle caractérisée par une destruction de cartilage, une formation d’ostéophytes et une inflammation au niveau de la membrane synoviale. Le 4-hydroxynonénal (HNE), un produit final de la peroxydation lipidique, a été identifié récemment comme un facteur catabolique et un médiateur inflammatoire dans le cartilage arthrosique humain. Notre projet vise à étudier l’effet du HNE sur la régulation de la prostaglandine E2 synthase-1 microsomale (mPGES-1) et de la protéine activante 5-lipoxygénase (FLAP)/5-lipoxygénase (5-LOX) dans les chondrocytes arthrosiques humains. Lorsque les cellules sont traitées une seule fois avec 10 µM HNE, les résultats de Western blot et de PCR en temps réel montrent que l’expression de la cyclooxygénase-2 (COX-2) et de la mPGES-1 augmente de manière significative et atteint respectivement le maximum après 8 et 16 heures d’incubation puis diminue graduellement. Cependant, lorsque les cellules sont traitées plusieurs fois avec 10 µM HNE à 2 heures d’intervalle, l’expression de la COX-2 et de la mPGES-1 augmente en fonction du temps sans subir une baisse après 24 heures d’incubation. Le HNE induit l’activité du promoteur de la mPGES-1 via l’activation du facteur de transcription Egr-1. L’investigation de la 2ème voie du métabolisme de l’acide arachidonique, à savoir 5-LOX/FLAP, montre que le HNE induit l’expression de FLAP après 24 heures de stimulation et celle de 5-LOX seulement après 48 heures. Ceci semble survenir à l’étape de transcription au cours de laquelle HNE induit l’expression de l’ARNm et l’activité du promoteur du gène 5-LOX. Nous avons démontré aussi que le niveau de leukotriène B4 (LTB4) augmente et suit le même profil que celui de la 5-LOX. L’étude des mécanismes moléculaires susceptibles d’être impliqués dans la régulation de la 5-LOX/FLAP par le HNE montre que ce dernier stimule leur expression via l’action de prostaglandine E2 (PGE2) et du facteur de croissance transformant-beta 1 (TGF-β1). En conclusion, notre étude démontre que le HNE induit à court-terme d’incubation la voie de COX-2/mPGES-1 puis par la suite stimule celle de FLAP/5-LOX à long-terme d’incubation dans les chondrocytes arthrosiques humains. Ces résultats suggèrent que la mPGES-1 et 5-LOX/FLAP sont des potentielles cibles thérapeutiques intéressantes pour contrôler la production de PGE2 et LTB4 dans OA. / 4-hydroxynonenal (HNE), a lipid peroxidation end-product, is produced abundantly in osteoarthritic (OA) articular tissues. Recently, we reported that HNE-induced cyclooxygenase-2 (COX-2) decreased gradually in human OA chondrocytes after 8 h of incubation. This study aimed to investigate whether COX-2 down-regulation is attributed to HNE depletion and is responsible for the switch from COX-2 to 5-lipoxygenase-activating protein (FLAP)/5-lipoxygenase (5-LOX). Treatment of chondrocytes with 10 µM HNE induced prostaglandin E2 (PGE2) release as well as COX-2 and microsomal prostaglandin E2 synthase-1 (mPGES-1) expression at the protein and mRNA levels, with a plateau reached at 8-16 h of incubation, followed by a subsequent decline. However, 8 repeated treatments with 10 µM HNE prevented the reduction of COX-2 and mPGES-1 expression. We demonstrated that HNE induced mPGES-1 promoter activity mainly through transcription factor Egr-1 activation. On the other hand, when COX-2 expression decreased, leukotriene B4 (LTB4) level rose after a long period of stimulation (48 and 72 h). At the mRNA level, HNE induced FLAP and 5-LOX expression after 24 and 48 h of stimulation, respectively. The addition of a nonspecific COX-2 inhibitor (naproxen) to cultured chondrocytes revealed that FLAP and 5-LOX regulation by HNE required PGE2 production. Furthermore, our data showed that 10 µM HNE significantly induced transforming growth factor-beta 1 (TGF-β1) production. The addition of anti-TGF-β antibody to culture medium reduced HNE-induced 5-LOX/FLAP expression by 40%, indicating the involvement of a TGF-β1-dependent mechanism. Our data demonstrate that the shunt to the FLAP/5-LOX pathway in HNE-induced human OA chondrocytes is attributed to COX-2 inhibition, probably due to HNE depletion. PGE2 and TGF-β1 are suggested to be involved in this regulation. Further experiments are in progress to determine other molecular mechanisms underlying this switch in OA chondrocytes.

The production of viable germ cells during human embryonic development determines adult reproductive success. This is particularly true for females, as development of germ cells (GCs) into primordial follicles before birth is imperative for future fertility. During fetal development GCs migrate to the genital ridge to form the gonad, after which several tightly regulated events, including proliferation, differentiation, and association with somatic cells, must occur to form a functional gonad. In the ovary these processes also include the initiation and subsequent arrest of meiosis. These developmental processes are orchestrated by local autocrine and paracrine factors, many of which remain to be identified in the human. In order to decipher further the pathways by which the gonad and GCs develop, potential regulators including prostaglandin (PG) E2, the interleukin (IL)6-type cytokines, and the prokinetecins (PROKs), were examined in the human fetal ovary and PROKs in the human fetal testis. Patterns of gene expression, protein localisation, function, and interaction of the potential mediators throughout human development (8-20 weeks gestation) were determined. Primary fetal tissue was investigated, in addition to immortalized GCs (T-Cam2 cells) and a murine model of fetal ovarian development. PGE2 interacts with known regulators of GC development in non-reproductive organs. It was postulated PGE2 may regulate GC progression by modulating these factors. Examination of PGE2 receptors and precursor enzymes in the fetal ovary revealed that all were present and some were developmentally regulated, with mRNA expression increasing with gestation. These developmentally regulated components were localised to the GCs. The PGE2 receptors were among those differentially expressed, with one localised solely to mature GCs. Culture of human fetal ovary confirmed that PGE2 regulates known regulators of GC development, increasing expression of survival and anti-apoptotic factors. To test the hypothesis that PGE2 is necessary for female GC development, paracetamol, an inhibitor of PGE2 precursor enzymes, was utilised in a murine model of fetal exposure. Fetal ovaries from this experiment displayed disruption of normal development. The IL6-type cytokines are also postulated to be involved in early gonad development, and are known to regulate proliferation and differentiation of mouse embryonic stem and GCs in vitro. A significant increase in transcript levels of the shared receptor components was determined in second trimester human ovaries, as well as developmental increases of several of the IL6-type ligands. Both common receptor components were located specifically in the GCs identifying them as the target of IL6 action in the human fetal ovary. The PROKs regulate cell migration, proliferation and differentiation, and modulate secretion of PGE2 and expression of some IL6-type cytokines. To-date, PROKs have not been examined in the human fetal gonad. Transcript levels were higher in the fetal testis compared to the ovary, with receptor and ligand components increasing with gestation. Most components also increased with gestation in the ovary. However, location of PROK components was strikingly different between the two tissues, with GCs being the primary target of PROK action in the fetal ovary, and Leydig and interstitial cells being the target in the testis. PROKs interaction with other regulators of gonad development was examined utilising a GC line in the case of the ovary and primary interstitial cell cultures in the case of the testis. These studies have identified new factors involved in human fetal gonad development, and how they interact with known regulatory pathways of development.

The incidence of chronic kidney disease (CKD) is increasing. CKD is characterized by a gradual decrease in renal function leading to end stage renal disease (ESRD). Damage to the glomerular podocytes, is one of the first hallmarks of CKD. We hypothesized that podocyte prostaglandin E2 (PGE2) receptors contribute to the progression of glomerular injury in models of CKD. To test this hypothesis, transgenic mice were generated with either podocyte-specific overexpression or deletion of the PGE2 EP4 receptor (EP4pod+and EP4pod-/- respectively). Mice were next tested in the 5/6 nephrectomy (5/6 Nx) or angiotensin II (Ang II) models of CKD. These studies revealed increased proteinuria and decreased survival for EP4pod+ mice while EP4pod-/- mice were protected against the development of glomerular injury. Furthermore, our findings were supported by in vitro studies using cultured mouse podocytes where an adhesion defect was uncovered for cells overexpressing the EP4 receptor. Additionally, our investigations have demonstrated a novel synergy between angiotensin II AT1 receptors and prostaglandin E2 EP4 receptors. This was revealed by in vitro studies using isolated mouse glomeruli. There we were able to show that Ang II stimulation leads to increased expression of cyclooxygenase 2 (COX-2), the enzyme responsible for synthesis of PGE2, in a p38 mitogen activated protein kinase (MAPK) dependent fashion. Moreover increased PGE2 synthesis was measured in response to Ang II stimulation. We confirmed the presence of this synergy in our cultured mouse podocytes and showed an adhesion defect in response to Ang II stimulation which was COX-2 and EP4 dependent. These findings suggest that Ang II AT1 receptors and PGE2 EP4 receptors act in concert to exacerbate glomerulopathies. Studies using mice with either podocyte-specific overexpression of a dominant negative p38 MAPK or mice with global deletion of the EP1 receptor did not provide conclusive results as to their respective signaling involvement in podocyte injury. Altogether our findings provide novel insight for podocyte PGE2 EP4 and Ang II AT1 receptor signaling in models of CKD. These studies provide novel avenues for pursuing therapeutic interventions for individuals with progressive kidney disease.

Abstract Screen modelling has traditionally been based on rudimentary empirical ‘factor’ methods, or semi-empirical data-fitting techniques. Both of these methods have significant limitations in practice, and industrial screen optimization remains somewhat of a ‘black art’. This thesis introduces the concept of dimensional analysis and scale model similitude to the problem of modelling vibrating screens. This leads to a new method of modelling industrial screens. A small-scale screen can be built at a more convenient scale in the laboratory, and used to predict the performance of a large industrial scale machine. Verification of the scaling theory is based on three separate methods: 1. Firstly, the scaling theory is developed by analysing particle-level forces acting in a dry granular system. It is shown that scale-up of granular systems can be achieved using Froude scaling: that is, if the geometry and operating variables in an experiment are scaled in a pre-defined manner, the behaviour of the particles in the full-scale can be predicted from the behaviour of the particles at the smaller scale. 2. Secondly, the scaling rules are applied to a number of idealized granular systems using numerical simulations via the discrete element method (DEM). The granular systems modelled include inclined vibrating feeders and inclined vibrating screens. It is found that simulations performed at different scales yield almost identical dimensionless responses when the geometry and operating conditions are scaled according to Froude scaling rules. 3. Thirdly, the scaling rules are applied to modelling physical screening data. A dataset obtained from a larger pilot-scale screen in a thesis by R. De Pretto (1992) is reproduced at a smaller scale in this thesis using a purpose-built laboratory-scale screen. The throughput, efficiency curves and cut size are shown to be predictable at all feed rates, despite the former dataset being based on a screen with a feed sample size of around 5000 kg per test and the latter dataset obtained using a feed sample size of less than 30 kg per test. The thesis also touches on modelling the screening efficiency curves. A fully dimensionless version of the proven and familiar Whiten screen model is proposed. Scale-up and modelling of industrial screens M. M. Hilden viii Finally, some of the further possibilities of this theory are discussed briefly in a section on further work; these include further applications of the Screening Physical Model and the application of Froude scaling to the modelling of other granular systems.

Thesis (Ph. D.)--University of Missouri-Columbia, 2005. / The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Vita. Includes bibliographical references.